Virpax Pharmaceuticals, Inc.
VRPXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708331
Virpax Pharmaceuticals, Inc. was delisted in 2025; its insiders filed their last Form 4 on Jul 10, 2024; 12 institutions reported holding it in 13F filings for Q4 2024, worth $46.7K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Virpax Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Virpax Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Field Katharyn | Director | – | Jul 10, 2024 | 0 |
| Herman Gary L | Director | – | Jul 9, 2024 | 0 |
| Dhaliwal Jatinder | Director | – | Jul 9, 2024 | 0 |
| Bruce Gerald W | Chief Executive Officer | – | Jan 31, 2024 | 0 |
| Shah Vinay | Chief Financial Officer | – | Jan 31, 2024 | 0 |
| Singh Vanila | Director | – | Jan 31, 2024 | 0 |
| Jambulingam Thani | Director | – | Jan 31, 2024 | 0 |
| Floyd Eric | Director | 8,018 | Jan 31, 2024 | 0 |
| Sendrow Jerrold | Director | 9,006 | Jan 31, 2024 | 0 |
| Dubin Michael F | Director | – | Jan 31, 2024 | 0 |
| Ruskin Barbara | Director | – | Jan 31, 2024 | 0 |
| Mathias Sheila | Chief Scientific Officer | – | Jan 31, 2024 | 0 |
| Mack Anthony P. | Chief Executive Officer | 252,562 | Feb 7, 2023 | 0 |
| Chipman Christopher Michael | Chief Financial Officer | – | Jan 27, 2023 | 0 |
| Gudin Jeffrey | Chief Medical Officer | – | Jan 27, 2023 | 0 |
| Jacob Gary S | Director | – | Jan 5, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 26, 2022 (view filing) | May 24 | 2 days | Sendrow JerroldDirector | PPurchaseCommon Stock, $0.00001 par value | +4.50K | $1.29 | +$5.80K | +99.9%9.01K after | |
| May 20, 2022 (view filing) | May 18 | 2 days | Mack Anthony P.Chief Executive Officer | PPurchaseCommon Stock, $0.00001 par value | +75.8K | $1.34 | +$101.5K | +42.8%252.6K after | |
| May 20, 2022 (view filing) | May 18 | 2 days | Floyd EricDirector | PPurchaseCommon Stock, $0.00001 par value | +4.48K | $1.36 | +$6.09K | +126.6%8.02K after | |
| Nov 24, 2021 (view filing) | Nov 22 | 2 days | Sendrow JerroldDirector | PPurchaseCommon Stock, $0.00001 par value | +3.90K | $3.93 | +$15.3K | +643.6%4.51K after | |
| Nov 22, 2021 (view filing) | Nov 18 | 4 days | Mack Anthony P.Chief Executive Officer | PPurchaseCommon Stock, $0.00001 par value | +25.1K | $3.99 | +$100.2K | +16.6%176.8K after |